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Accepted 13 October 2014Haploidentical stem cell transplantation (HSCT) has
become a favored approach for patients with marrow failure
states and high-risk malignancies who lack a suitable HLA-
matched donor [1]. To overcome severe acute graft-versus-
host disease (GVHD) as well as graft failure anticipated
with the mismatched HLA antigens, the initial approach was
to use T lymphocyteedepleted grafts andmega-doses of high
CD 34þ numbers [2]. Several groups have since resorted to
monoclonal antibody-based in vivo T lymphocyte immuno-
depletion using antithymocyte globulin or alemtuzumab
[1-3], while others resorted to post-transplantation cyclo-
phosphamide [4,5] to achieve in vivo T lymphocyte cytor-
eduction. This approach capitalizes on the rapid proliferation
of donor-derived alloreactive T lymphocytes, sparing natural
killer cells and aldehyde dehydrogenaseerich regulatory T
cells [6], thereby providing the much needed graft-versus-
leukemia effect while reducing the incidence of severe
acute GVHD. Emerging strategies for the prevention of
GVHD, such as T cell depletion, mammalian target of rapa-
mycin (mTOR) inhibition, the use of chemokine-cytokine
antagonists or novel regulators, such as atorvastatin and
bortezomib, epigenetic modulators with histone acetylase
inhibition, and hypomethylating agents, are currently being
evaluated in preclinical GVHD models and introduced in
allogeneic hematopoietic stem cell transplantation clinical
trials [7-9].DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.08.001.
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http://dx.doi.org/10.1016/j.bbmt.2014.10.013Granulocyte colonyestimulating factor (G-CSF) is a
recombinant cytokinewith pleotropic activities [10], affecting
proliferation and expansion ofmyeloid-committed progenitor
cells, hematopoietic aswell as leukemic stem cell proliferation
and paradoxical quiescence [11], as well as CD34þ stem/pro-
genitor cell mobilization [10] and acute myeloid leukemia
chemosensitization [12-14]. G-CSF is also recognized as a
tolerance-inducing cytokine, as it promotes the mobilization
of T helper 2einducing dendritic cells [15] andhas a tolerance-
promoting action independent of IL-10 [16]. Di Bartolomco
et al. have recently shown a beneﬁcial effect of G-CSFeprimed
bone marrow in the unmanipulated haploidentical trans-
plantation setting, with improved engraftment, incidence of
GVHD, and survival in patients with high-risk malignancies
using a chemotherapy-based conditioning regimen and GVHD
prophylaxis with antithymocyte globulin, cyclosporine,
methotrexate, mycophenolate mofetil, and anti-CD25 anti-
body [17]. This report set the stage for Gao et al. [18], who
determined the outcome of haploidentical stem cell trans-
plantation in high-risk malignancy patients using a combina-
tion of G-CSF priming during the chemotherapy conditioning
regimen as well as G-CSFemobilized peripheral blood
(>6.0 106/kg CD34þ cells) and bone marrow nucleated cells
(>4.0  108/kg). GVHD prophylaxis in this study used antith-
ymocyte globulin (Thymoglobulin, Genzyme Cambridge) at
2.5 mg/kg for 4 days (days 5 to 2). G-CSF at 5 mg/kg daily
was administered subcutaneously on days 10 to 7 of the
chemotherapy-based conditioning regimen, which consisted
of cyclohexyl nitrosourea 200 mg/m2 orally on day -9, high-
dose cytarabine 4 g/m2 daily on days 8 to 7, busulfan
3.2mg/kgdailyondays6 to4, and cyclophosphamide1.8g/
m2 daily on days3 to 2 [18]. Based on the known activities
of G-CSF [10-16], the use of G-CSF-mobilized peripheral blood
stem cells and the enhanced leukemic chemosensitization
with the combination of high-dose cytarabine plus G-CSF
priming in the conditioning regimen [12-14] allows one to
anticipate decreased GVHD and leukemia relapse.
However, another novel property of G-CSF has been
elucidated in the report of Boyd et al. [19] showing niche
displacement of human leukemic stem cells, thereby
C.N. Abboud / Biol Blood Marrow Transplant 20 (2014) 1873e18761874allowing the more efﬁcient and nimble normal hematopoi-
etic stem cells to home and repopulate the hematopoietic
stromal niches. The combined use of G-CSF priming and
augmented peripheral blood and marrow haploidentical
stem cell transplantation was associated with improved
cumulative leukemia-free survival and cumulative survival.
Although these ﬁndings are excellent in the context of
high-risk hematologic malignancies, they require corrobo-
ration from ongoing and/or future studies. The concept of
hematopoietic stem cell competition and displacement of
residual leukemic stem cells by G-CSF priming is a testable
hypothesis in preclinical transplantation models. These ad-
vances from our colleagues in China are welcome, as fully
matched HLA identical donors are not always available,
especially in minority populations and some ethnic groups.
Thus, modiﬁed haploidentical HSCTwill increasingly become
the favored technique to provide a fully ablative and/or
nonmyeloablative transplantation to high-risk patients with
hematologic malignancies [18,20]. The pioneering work of EJ
Fuchs has enabled future application of HSCT to nonmalig-
nant disease as well as solid organ transplantation. Finally,
“designed” grafts containing appropriate ratios of conven-
tional T lymphocytes and T regulatory cells, natural killer
cells, and other accessory cells will pave the road to
better immune reconstitution and less GVHD, eventually
avoiding the toxicity and expensive monitoring of post-
transplantation pharmacological prophylaxis [21,22].
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